10QSB 1 v030020_10qsb.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------ Form 10-QSB (Mark One) (X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2005 (_) TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from _________ to __________. Commission File number 0-935 ------------ MOLECULAR DIAGNOSTICS, INC. --------------------------- (Exact Name of Small Business Issuer as Specified in Its Charter) Delaware 36-4296006 -------- ---------- (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 414 North Orleans Street, Suite 502 Chicago, IL 60610 ----------------- (Address of Principal Executive Offices) (312) 222-9550 ----------------- (Issuer's Telephone Number, including Area Code) N/A ----------------- (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes |X| No |_| Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes |_| No |X| The number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: Common Stock, $0.001 par value, at November 14, 2005: 154,354,735 ----------- MOLECULAR DIAGNOSTICS, INC. QUARTERLY REPORT ON FORM 10-QSB TABLE OF CONTENTS Page ---- PART I. -- FINANCIAL INFORMATION Item 1. Financial Statements a) Consolidated Balance Sheets -- September 30, 2005 (unaudited) and December 31, 2004 ......................................... 3 b) Consolidated Statements of Operations -- Three and nine months ended September 30, 2005 and September 30, 2004 (all unaudited) .................................................... 4 c) Consolidated Statements of Cash Flows -- Nine months ended September 30, 2005 and September 30, 2004 (all unaudited) ..... 5 d) Notes to Consolidated Financial Statements ...................... 6 Item 2. Management's Discussion and Analysis or Plan of Operation ........ 19 Item 3. Controls and Procedures .......................................... 24 PART II. -- OTHER INFORMATION Item 1. Legal Proceedings ................................................ 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds ...... 24 Item 3. Defaults upon Senior Securities .................................. 25 Item 4. Submission of Matters to a Vote of Security Holders .............. 28 Item 5. Other Information ................................................ 28 Item 6. Exhibits ......................................................... 29 SIGNATURES ............................................................... 29 EXHIBIT INDEX ............................................................ 30 2 PART I. -- FINANCIAL INFORMATION Item 1. Financial Statements MOLECULAR DIAGNOSTICS, INC. CONSOLIDATED BALANCE SHEETS (Dollars in thousands)
September 30, December 31, 2005 2004 ------------- ------------ (Unaudited) Assets Current Assets: Cash and cash equivalents ..................................................................... $ 130 $ 11 Accounts receivable, net of allowance for doubtful accounts of $0 at September 30, 2005 and December 31, 2004 .................................................................. 16 30 Inventories ................................................................................... 48 48 Prepaid financing costs ....................................................................... -- 80 Prepaid expenses and other current assets ..................................................... 121 14 ------------- ------------ Total current assets ...................................................................... 315 183 Fixed Assets, net ............................................................................... 258 326 Other Assets: Licenses, patents and technology, net of amortization ......................................... 20 20 ------------- ------------ Total assets .............................................................................. $ 593 $ 529 ============= ============ Liabilities and Stockholders' Equity (Deficit) Current Liabilities: Accounts payable .............................................................................. $ 3,989 $ 4,426 Accrued payroll costs ......................................................................... 1,044 1,084 Accrued expenses .............................................................................. 1,838 1,944 Deferred revenue .............................................................................. 25 25 Due to stockholder ............................................................................ 36 38 Lease obligation .............................................................................. 110 110 Notes payable--related parties ................................................................ 70 70 Notes payable ................................................................................. 3,560 4,955 ------------- ------------ Total current liabilities ................................................................. 10,672 12,652 ------------- ------------ Stockholders' Equity (Deficit): Preferred stock, $0.001 par value; 10,000,000 shares authorized; 1,102,192 and 1,119,192 shares issued and outstanding at September 30, 2005 and December 31, 2004, respectively (Liquidation value of preferred stock $9,459,022) .......................................................... 7,716 7,767 Common stock, $0.001 par value; 300,000,000 shares authorized; 154,546,823 and 99,792,292 shares issued and 154,354,735 and 99,600,204 shares outstanding at September 30, 2005 and December 31, 2004, respectively ............................................................................ 155 100 Additional paid-in-capital ...................................................................... 50,017 45,961 Treasury stock: 192,088 shares at September 30, 2005 and December 31, 2004 ...................... (327) (327) Accumulated deficit ............................................................................. (67,586) (65,565) Accumulated comprehensive loss-- Cumulative translation adjustment ........................................................... (55) (59) ------------- ------------ Total stockholders' equity (deficit) ...................................................... (10,080) (12,123) ------------- ------------ Total liabilities and stockholders' equity (deficit) ...................................... $ 593 $ 529 ============= ============
The accompanying notes are an integral part of these consolidated financial statements. 3 MOLECULAR DIAGNOSTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts)
For the Nine Months For the Three Months ended September 30, ended September 30, ----------------------------- ----------------------------- 2005 2004 2005 2004 ------------- ------------ ------------- ------------ (Unaudited) (Unaudited) Net revenues ............................................. $ 93 $ 195 $ 24 $ 41 Operating expenses Cost of revenues ....................................... -- 25 -- -- Research and development ............................... 128 716 31 231 Selling, general, and administrative ................... 1,047 3,254 (55) 1,116 ------------- ------------ ------------- ------------ Total operating expenses ........................... 1,175 3,995 (24) 1,347 ------------- ------------ ------------- ------------ Operating loss ........................................... (1,082) (3,800) 48 (1,306) Other income (expense): Interest expense - related party ....................... (7) (50) (2) (2) Interest expense ....................................... (932) (1,546) (124) (409) Other, net ............................................. -- 10 -- -- ------------- ------------ ------------- ------------ Total other income (expense) ....................... (939) (1,586) (126) (411) ------------- ------------ ------------- ------------ Loss before income taxes ................................. (2,021) (5,386) (78) (1,717) Provision for income taxes ............................... -- -- -- -- ------------- ------------ ------------- ------------ Net loss ............................................. (2,021) (5,386) (78) (1,717) Preferred stock dividend in arrears ...................... (683) (802) (230) (232) ------------- ------------ ------------- ------------ Net loss applicable to common stockholders ............... $ (2,704) $ (6,188) $ (308) $ (1,949) ============= ============ ============= ============ Basic and fully diluted net loss per common share ........ $ (0.02) $ (0.09) $ (0.00) $ (0.02) ============= ============ ============= ============ Weighted average number of common shares outstanding ..... 111,137,400 71,054,095 118,669,134 83,374,666 ============= ============ ============= ============
The accompanying notes are an integral part of these consolidated financial statements. 4 MOLECULAR DIAGNOSTICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in thousands)
Nine Months Ended September 30, ------------------ 2005 2004 ------- ------- (Unaudited) Operating Activities: Net loss ........................................................................... $(2,021) $(5,386) Adjustments to reconcile net loss to net cash used for operating activities: Amortization of debt discount .................................................... 575 905 Depreciation and amortization .................................................... 92 514 Amortization of prepaid consulting fees .......................................... 79 319 (Gain) loss on sale of fixed assets .............................................. 3 (99) Note issued in payment of an expense ............................................. 82 103 Warrants issued in settlement .................................................... 421 -- Compensation expense related to stock appreciation rights ........................ -- 149 Return of fixed assets in exchange for relief of indebtedness .................... -- 1,158 Changes in assets and liabilities: Accounts receivable, net ....................................................... 14 12 Inventories .................................................................... -- 19 Due to stockholder ............................................................. (1) (15) Prepaid expenses and other current assets ...................................... (107) (124) Checks issued in excess of amounts on deposit .................................. -- (5) Accounts payable ............................................................... (229) (1,100) Lease obligation ............................................................... -- (183) Deferred revenue ............................................................... -- (50) Accrued expenses ............................................................... (135) 343 ------- ------- Net cash used for operating activities ............................................. (1,227) (3,440) ------- ------- Investing Activities: Expenditures for licenses, patents and technology .................................. -- (20) Purchases of fixed assets .......................................................... (27) (187) Proceeds from sale of fixed assets ................................................. -- 28 ------- ------- Net cash used for investing activities ............................................. (27) (179) ------- ------- Financing Activities: Proceeds from issuance of convertible notes payable ................................ -- 4,236 Net proceeds from issuance of common stock ......................................... 1,378 275 Payment of notes payable ........................................................... (5) (890) Note issued in payment of an expense ............................................... -- 103 ------- ------- Net cash provided by financing activities .......................................... 1,373 3,621 ------- ------- Net increase in cash and cash equivalents ............................................ 119 2 Cash and cash equivalents at beginning of period ..................................... 11 -- ------- ------- Cash and cash equivalents at end of period ........................................... $ 130 $ 2 ======= ======= Supplemental disclosure of cash flow information: Cash paid during the period for: Interest ....................................................................... $ 28 $ 135 Financing costs ................................................................ $ 58 $ -- Non-cash transactions during the period for: Financing costs ................................................................ $ 93 $ 1,067 Preferred stock and cumulative dividends converted into common stock ........... $ 71 $ 6,353 Convertible promissory notes and accrued interest converted into common stock... $ 6,884 $ --
The accompanying notes are an integral part of these consolidated financial statements. 5 MOLECULAR DIAGNOSTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Note 1. Organization Molecular Diagnostics, Inc. ("MDI" or the "Company") was incorporated as Ampersand Medical Corporation in Delaware in December 1998 as the successor to Bell National Corporation ("Bell National"). Bell National was incorporated in California in 1958, and was the continuing legal entity following its acquisition of InPath, LLC, a development-stage company engaged in the design and development of medical instruments and related tests, in December 1998. Bell National then merged into the Company, which was then operating under the Ampersand name, in 1999. On September 25, 2001, following the Company's acquisition of AccuMed International, Inc. ("AccuMed") via the merger of AccuMed into a wholly-owned subsidiary of MDI, the Company changed its corporate name to Molecular Diagnostics, Inc. in order to better represent its operations and products. The name change was effected through a merger with a separate wholly-owned subsidiary. MDI retained its Certificate of Incorporation in the merger, except as amended to reflect its new name, bylaws and capitalization. MDI is a bio-molecular diagnostics company focused on the design, development and commercialization of cost-effective screening systems to assist in the early detection of cancer, including its InPath(TM) System and related image analysis systems. MDI, however, has currently curtailed its operations and expects to resume such operations only when the Company has obtained additional capital. The InPath System and related products are intended to detect cancer and cancer-related diseases, and may be used in a laboratory, clinic, or doctor's office. In addition to AccuMed and Oncometrics Imaging Corp., a wholly-owned subsidiary of AccuMed, MDI had another wholly-owned subsidiary, Samba Technologies, Sarl ("Samba"). MDI lost all rights and title to the assets of Samba upon completion of the former subsidiary's bankruptcy liquidation sale in December 2003. The Company has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement MDI's business plan and develop, manufacture and market its products. These circumstances raise substantial doubt about MDI's ability to continue as a going concern. Implementation of the Company's plans and its ability to continue as a going concern depend upon its securing substantial additional financing. During the first nine months of 2005, MDI raised net proceeds of $1,377,762 through the sale of its common stock. Management's plans for the remainder of fiscal 2005 include substantial efforts to obtain additional capital. During the quarter ended September 30, 2005, however, the Company was unable to obtain adequate financing or generate profitable sales revenues, and was forced to curtail its product development and other activities. If the Company continues to be unable to obtain adequate financing to fund operations, it will be forced to cease operations and may seek bankruptcy protection. Note 2. Basis of Presentation The consolidated financial statements for the periods ended September 30, 2005 and 2004 included herein are unaudited. Such financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated and in order to make the financial statements not misleading. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2005 or for any other period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. These financial statements should be read in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004 as filed with the SEC. 6 Note 3. Summary of Significant Accounting Principles The accounting policies and principles management believes are most critical to aid in understanding and evaluating the Company's reported financial results include the following: Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition. MDI recognizes revenue in accordance with Staff Accounting Bulletin No. 104, "Revenue Recognition," when the following criteria are met: shipment of a product or license to customers has occurred and there are no remaining Company obligations or contingencies; persuasive evidence of an arrangement exists; sufficient vendor-specific, objective evidence exists to support allocating the total fee to all elements of the arrangement; the fee is fixed or determinable; and collection is probable. Revenue from ongoing client maintenance is recognized ratably over the post-contract support term, which is generally 12 months. Revenue from training services and professional services is recognized when the service is completed. Revenue from implementation and installation services is recognized using the percentage of completion method. Implementation and installation services are generally completed within 120 days. Research and Development Costs. Research and development costs are charged to operations as incurred. MDI conducts a portion of its research activities under contractual arrangements with scientists, researchers, universities, and other independent third parties. Foreign Currency Translation. The functional currency of the Company's foreign operations is the local currency. Accordingly, all assets and liabilities are translated into U.S. dollars using period-end exchange rates, and all revenues and expenses are translated using average exchange rates during the year. Net Loss Per Share. Basic loss per share is calculated based on the weighted-average number of outstanding common shares. Shares issued and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated based on the weighted-average number of outstanding common shares plus the effect of dilutive common shares. MDI's calculation of diluted net loss per share as reported excludes potential common shares, as the effect would be anti-dilutive. Restructuring Settlements. Restructuring settlements reflect the difference between the actual settlement amounts for various litigation and creditor payment matters and the amounts originally recorded on the Company's financial statement as the amount due. Settlement amounts were less than amounts originally recorded in recognition of the Company's financial condition. Share-Based Payment. In December 2004, FASB issued Statement of Financial Accounting Standards No. 123(revised), "Share-Based Payment" ("SFAS No. 123(R)"), which revised SFAS No. 123, "Accounting for Stock-Based Compensation" ("SFAS No. 123"). SFAS No. 123(R) establishes accounting standards for transactions in which a company exchanges its equity instruments for goods or services. In particular, the statement will require companies to record compensation expense for all share-based payments, such as employee stock options, at fair market value. This statement is effective for the Company as of the beginning of the next fiscal year that begins after December 15, 2005. Adoption of this financial statement is not expected to have a material impact on the Company's consolidated financial position or results of operations. 7 Note 4. Licenses, Patents and Technology Licenses, patents, and purchased technology are recorded at their acquisition cost. Costs to prepare patent filings are expensed when incurred. Costs related to abandoned patents or denied patent applications are written off at the time of abandonment or denial. Amortization is begun as of the date of acquisition or upon the grant of the final patent. Costs are amortized over the asset's useful life, which ranges from two to 17 years. At each annual balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. Licenses, patents, and technology were as follows: (in thousands) September 30, December 31, 2005 2004 ------------- ------------ (unaudited) Licenses ...................................... $ 20 $ 20 Patent costs .................................. 133 133 LabCorp Technology Agreement .................. 260 260 ------------- ------------ Subtotal ...................................... 413 413 Less accumulated amortization ................. (393) (393) ------------- ------------ Total ................................... $ 20 $ 20 ============= ============ In 2004, MDI was party to a legal settlement with MonoGen, Inc. involving technology owned by MDI's subsidiary, AccuMed. The dispute was resolved, resulting in the transfer to MonoGen of all of MDI's rights and title to certain AccuMed intellectual property. The transferred technology is not used in the Company's InPath(TM) cervical screening system. The settlement resulted in a net $5,919,000 loss reflected in adjustments to the MDI Technology Agreement and accumulated amortization balances as of December 31, 2004. In 2004, MDI was also party to a legal settlement with Invirion, Inc. and Dr. Bruce Patterson over the validity of a technology license. Pursuant to the settlement agreement, MDI agreed to the cancellation of the license, which resulted in a net $569,000 loss reflected in adjustments to the license and accumulated amortization balances as of December 31, 2004. For the nine months ended September 30, 2005 and 2004, amortization expense was $0 and $263,000, respectively. Note 5. Accrued Expenses Accrued expenses included the following: (in thousands) September 30, December 31, 2005 2004 ------------- ------------ (unaudited) Accrued interest ............................... $ 829 $ 994 Accrued interest--related party ................ 32 25 Accrued settlement costs ....................... 438 438 Accrued franchise and other taxes .............. 389 476 Other accrued expenses ......................... 150 11 ------------- ------------ Total .................................... $ 1,838 $ 1,944 ============= ============ MDI was delinquent in paying a portion of its federal and state employee and employer payroll taxes for 2003, 2002, and 2001. The delinquent federal payroll taxes relating to 2003 and 2002 were paid in full in April 2004. The delinquent federal and state payroll taxes relating to 2001 were paid in full during the nine months ended September 30, 2005. 8 The Company owed $0 and $97,000 as of September 30, 2005 and December 31, 2004, respectively, for 2001 federal payroll taxes, and amounts related to 2004 were included in accrued payroll costs in the accompanying December 31, 2004 balance sheet. MDI is also delinquent in filing certain federal and state income tax returns for 2004, 2003 and 2002 and is working to complete and file the returns. MDI does not expect to owe federal and state income taxes for 2004, 2003 and 2002. The delinquent federal and state income tax returns for 2001 were filed in March 2005 with zero tax due. Note 6. Notes Payable--Related Parties Notes payable to related parties consisted of: (in thousands) September 30, December 31, 2005 2004 ------------- ------------ (unaudited) Northlea Partners, Ltd., $25,000 Promissory Note issued August 6, 2001; interest rate 15% per annum ........................................ $ 25 $ 25 Northlea Partners, Ltd., $15,000 Promissory Note issued September 20, 2001; interest rate 9% per annum .................................... 15 15 Northlea Partners, Ltd., $15,000 Bridge II Convertible Promissory Note issued May 1, 2003; interest rate 12% per annum (see description under Bridge II Notes in Note 7-Notes Payable for other terms and conditions) .................................. 15 15 Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum ........................................ 15 15 ------------- ------------ $ 70 $ 70 ============= ============ Peter Gombrich Amounts Due. Peter Gombrich, the Company's former Chairman and CEO, was owed $36,481 and $37,299 at September 30, 2005 and December 31, 2004, respectively, for previous advances to the Company. MDI has classified the amount due to Mr. Gombrich under the current liabilities heading "Due to stockholder" in the accompanying balance sheets. Carrying Amounts. Management believes it is not practicable to estimate the fair value of the notes payable-related parties due to the uncertainty regarding repayment, the possible conversion of amounts due into stock of the Company, and the Company's current financial condition. Note 7. Notes Payable Notes payable to unrelated parties consisted of: (in thousands) September 30, December 31, 2005 2004 ------------- ------------ (unaudited) Bridge I Convertible Promissory Notes; due December 31, 2002; interest rate 7% per annum; convertible into common stock at 75% of the market price on date of conversion; beneficial conversion feature valued at $1,042,000 at June 30, 2002; warrants at an exercise price of $0.25 per share; additional warrants at an exercise price equal to 150% of note conversion price ............................. $ 500 $ 750 Bridge II Convertible Promissory Notes; due July 31, 2004; interest rate 12% or 15% per annum; convertible into common stock at $0.10 or $0.15 per share; beneficial conversion feature valued at $1,777,000 and $330,000 at December 31, 2003 and December 31, 2002, respectively; warrants at an exercise price of $0.15 or $0.20 per share .............................. 1,285 1,285 Bridge III Convertible Promissory Notes; due December 31, 2008; interest rate 10% per annum; convertible into common stock at $0.10 per share; beneficial conversion feature valued at $1,604,000 at June 30, 2004; warrants at an exercise price of $0.15 per share ........................................ 116 268 9 Bridge IV Convertible Promissory Notes; due December 31, 2008; interest rate 10% per annum; convertible into common stock at $0.10 per share; beneficial conversion feature valued at $1,791,000 at June 30, 2004; warrants at an exercise price of $0.15 per share; ....................................... -- 1,085 Monsun, AS $500,000 Promissory Note issued November 1, 2000; interest rate 20% per annum, compounded into principal amount; beneficial conversion feature valued at $125,000 at November 1, 2000 ............................. 907 782 MonoGen, Inc. $305,000 Promissory Note issued October 14, 2004; interest rate 14% per annum; first installment of $25,000 due November 1, 2004 with monthly principal and interest installments of $10,000 thereafter; due January 1, 2007 .............................. 305 305 O.P., LLC $29,390 Promissory Note issued May 12, 2003; interest rate 7% per annum; monthly principal payments of $1,316 plus interest commencing June 1, 2003; ..................... -- 6 Ungaretti and Harris LLP $211,368 Secured Promissory Note issued May 8, 2003; interest rate 12% per annum; due September 30, 2003 ... 127 149 Ernst & Young LLP $30,800 Promissory Note issued July 17, 2003; interest rate 12% per annum commencing January 1, 2003; due December 31, 2003 ......................................... 31 31 Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; due December 31, 2003; interest rate 8% per annum payable after December 31, 2003 ...................... 21 21 Xillix Technologies Corporation $361,000 Promissory Note issued June 26, 1998; interest rate Canadian Prime plus 6% per annum; represents a debt of AccuMed ................. 34 34 Western Economic Diversification $221,000 Promissory Note issued June 1989; no interest; represents a debt of Oncometrics ............. 234 239 ------------- ------------ $ 3,560 $ 4,955 ============= ============ Bridge I. In 2002, MDI issued an aggregate $3,185,000 in Bridge I Convertible Promissory Notes to accredited investors. The notes bear interest at the rate of 7% per annum and are convertible at any time into the common stock of MDI at a conversion price equal to 75% of the market price of the Company's common stock on the date of conversion. In addition, MDI issued to each holder a warrant that entitled each such holder to purchase one share of common stock at an exercise price of $0.25 per share for each dollar of principal. MDI calculated a fair value of $99,950 for these warrants using the fair value interest rate method and recorded this amount as additional interest expense during 2002. In addition, at the time of conversion of the note, each holder is entitled to receive a warrant to purchase one share of common stock for each four shares of common stock into which the note converts at an exercise price equal to 150% of the conversion price of the note. MDI has not determined a value for these warrants as of September 30, 2005. Since the conversion price of the note is at a 25% discount to the market price of the common stock of MDI, the holder is considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,042,000 at June 30, 2002. In February 2003, a note holder, NeoMed Innovations III, converted $1,060,000 in principal amount of Bridge I notes into Bridge II notes. In November 2003, two Bridge I note holders converted $50,000 in principal amount of notes and $5,287 in accrued interest into 368,579 shares of unregistered common stock. Management extended a written offer, dated October 10, 2003, to the Bridge I noteholders to convert their notes and accrued interest into common shares at a conversion rate of $0.15 per share. In addition, the Bridge I holders were offered warrants to purchase one new share for every four shares acquired by the noteholder upon exercise of such holder's conversion rights under the notes. This offer continued to remain outstanding as of September 30, 2005. During the twelve months ended December 31, 2004, holders of an aggregate $1,325,000 principal amount of Bridge I Convertible Promissory Notes elected to convert their notes and related accrued interest of approximately $173,000 into 9,985,182 shares of unregistered common stock. For the nine months ended September 30, 2005, holders of $250,000 principal amount of Bridge I Convertible Promissory Notes elected to convert their notes and related accrued interest into 2,008,962 of unregistered common stock. The remaining $500,000 in principal Bridge I notes remained unconverted and outstanding at September 30, 2005. 10 Bridge II. Beginning in October 2002, MDI began an issue of up to $4,000,000 in Bridge II Convertible Promissory Notes to accredited investors. MDI issued $550,000 in Bridge II notes as of December 31, 2002. From January 1, 2003 through the closing of the offering on December 5, 2003, MDI issued Bridge II notes in the principal amount of: $1,980,200 in exchange for cash, $1,060,000 as a conversion of a Bridge I Convertible Promissory Note (see discussion above) and $305,667 in exchange for a note payable to Peter P. Gombrich, the Company's then-Chairman, for a total issuance during fiscal year 2003 of $3,345,867. The notes as originally issued provide for interest at a rate of 12% per annum payable at the maturity date in kind in the form of shares of common stock of MDI. The Company granted the holders a junior security position in all of its assets. The notes are convertible at any time into the common stock of MDI. The note conversion price and the value of common shares paid in kind as interest for the first $1,000,000 in principal amount of cash subscriptions, determined on a "first come - first served basis," is $0.10 per share. The note conversion price and the value of common shares paid in kind as interest for the remaining $3,000,000 of principal amount of notes in the series is $0.15 per share. The conversion prices of the notes issued during 2002 and 2003 were less than the market price of the common stock when the notes were issued; therefore, the holders are considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,777,200 and $330,000 at December 31, 2003 and 2002, respectively. The value was recorded as a reduction of the debt and amortized as additional interest over the life of the notes. MDI recorded additional interest expense of $334,909 to reflect amortization of the discount during the twelve months ended December 31, 2004, which represented the final amortization of the beneficial conversion feature. At the time MDI completes significant additional funding plans, as outlined in the subscription agreement for the Bridge II notes, each holder of Bridge II notes is entitled to receive a warrant to purchase one share of the common stock of the Company for each four shares of common stock into which the note is convertible at an exercise price of $0.15 per share for notes in the class pertaining to the first $1,000,000 in subscriptions and $0.20 for the remaining $3,000,000 in note principal subscriptions. In September 2003, an amendment to the Bridge II Convertible Promissory Notes was sent to holders requesting an extension of the notes to July 31, 2004. As additional consideration for the extension, holders were offered an increase in the interest rate from 12% to 15%. In addition, an amendment to the indenture also offered an increase in the warrant coverage ratio from 25% to 33%. The Bridge II offering was closed as of December 5, 2003. For the 12 months ended December 31, 2004, holders of an aggregate $2,146,000 in principal amount of Bridge II Convertible Promissory Notes elected to convert their notes and related accrued interest of approximately $251,000 into 17,619,242 shares of unregistered common stock. Included in such conversion amounts are amounts due Peter P. Gombrich, the Company's former Chairman, of $305,667 in Bridge II principal and $11,431 in accrued interest thereon, which were converted into an aggregate 2,113,987 shares of unregistered common stock. The remaining $1,300,000 in principal Bridge II notes remain unconverted and outstanding at September 30, 2005. Bathgate Capital Partners, LLC - Bridge III. Beginning in January 2004, Bathgate Capital Partners, LLC began an offering of a maximum of $4,000,000 and a minimum of $1,500,000 in Bridge III Convertible Promissory Notes to accredited investors on behalf of the Company. The notes bear interest at 10% per annum payable, on a semi-annual basis, in kind in the form of shares of common stock for the first two years and then in cash for the remaining three years until due December 31, 2008. The note conversion price and the value of common shares paid in kind as interest is $0.10 per share. The notes are convertible at any time into the common stock of MDI, although the notes will automatically convert if the last sales price of the stock is $0.30 or higher for 20 consecutive trading days, the daily average trading volume is at least 250,000 shares, and the underlying shares are registered for sale. The holders were also granted a security interest in all of the Company's assets. MDI granted each note holder the right to receive 25% warrant coverage on all money invested; therefore, for every $100,000 invested, an investor will receive warrants to purchase 25,000 shares of common stock at an exercise price of $0.15 per share. The warrants expire on December 31, 2008. The Bridge III offering documents provided that funds raised would not be released from escrow until the following requirements were met: o A minimum investment of $1,500,000 had been reached; o The $190,000 Convertible Promissory Note held by Suzanne Gombrich, wife of Peter Gombrich, was converted into common shares; o A portion of the Bridge II Convertible Promissory Note holders converted their notes into common shares; and o Peter P. Gombrich, MDI's then-current Chairman and CEO, would resign his position as CEO of the Company. 11 With the exception of the conversion of Suzanne Gombrich's $190,000 note, which was converted following stockholder approval of an increase in the number of authorized shares of common stock of the Company in July 2004, these requirements were satisfied on April 2, 2004 and the Company issued $1,500,000 in convertible promissory notes in exchange for cash. The funds were used for repayment of a $1 million convertible note held by Suzanne Gombrich, payment of taxes, and working capital. On May 21, 2004, the Company issued an additional $162,500 in Bridge III notes in exchange for cash. The conversion prices of the notes issued during 2004 were less than the market price of the common stock when the notes were issued; therefore, the holders are considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,604,000 at June 30, 2004. The value was recorded as a reduction of the debt and will be amortized as additional interest over the life of the notes. MDI recorded additional interest expense of $206,451 and $208,595 to reflect amortization of the discount during the nine months ended September 30, 2005 and the 12 months ended December 31, 2004, respectively. At the conclusion of the offering, the Company had issued an aggregate $1,662,500 in principal amount of Bridge III Convertible Promissory Notes in exchange for cash. As of September 30, 2005, holders of Bridge III Convertible Promissory Notes had elected to convert an aggregate $1,559,518 note principal and accrued interest into 15,282,236 unregistered common shares. The remaining $302,500 in principal Bridge III notes remain unconverted and outstanding at September 30, 2005. Bridge IV. Beginning in February 2004, MDI began a separate offering of Bridge IV Convertible Promissory Notes to accredited investors. The notes bear interest at 10% per annum payable, on a semi-annual basis, in kind in the form of shares of common stock for the first two years and then in cash for the remaining three years until the December 31, 2008 maturity date. The note conversion price and the value of common shares paid in kind as interest is $0.10 per share. The conversion prices of the notes during 2004 were less than the market price of the common stock when the notes were issued; therefore, the holders are considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,791,000 at June 30, 2004. The value was recorded as a reduction of the debt and will be amortized as additional interest over the life of the notes. MDI recorded additional interest expense of $192,558 and $302,288 to reflect amortization of the discount during the nine months ended September 30, 2005 and the 12 months ended December 31, 2004, respectively. The notes are convertible at any time into the common stock of MDI, although the notes will automatically convert if the last sales price of the stock is $0.30 or higher for 20 consecutive trading days, the daily average trading volume is at least 250,000 shares, and the underlying shares are registered for sale. The holders were also granted a security interest in all of the Company's assets. MDI granted each note holder the right to receive 25% warrant coverage on all money invested; therefore, for every $100,000 invested, an investor will receive warrants to purchase 25,000 shares of common stock at an exercise price of $0.15 per share. The warrants expire on December 31, 2008. At the conclusion of the offering, the Company had issued an aggregate $2,573,500 in principal amount of Bridge IV Convertible Promissory Notes in exchange for cash. As of September 30, 2005, all holders of Bridge IV Convertible Promissory Notes had elected to convert an aggregate $2,573,505 principal amount in exchange for 25,605,000 unregistered common shares. As of September 30, 2005, the Bridge IV note holders representing over 85% of the total principal note amounts also elected to waive $328,477 accrued interest resulting in one-time interest forgiveness income for the quarter then ended. Monsun. On November 1, 2000, MDI issued a convertible promissory note to Monsun, AS ("Monsun") in exchange for $500,000 in cash. The note originally bore interest at the rate of 15% per year and was originally due 12 months from the date of issue. The note is convertible into common stock, any time after the expiration of the first 180 days of the loan term, at a conversion price of $1.00 per share. On October 31, 2001, Monsun and MDI agreed to the first extension of the maturity date of the note until January 31, 2002. As consideration for the first extension agreement, MDI issued a three-year warrant to Monsun, entitling the holder to purchase 100,000 shares of common stock of MDI at an exercise price of $0.60 per share. On January 31, 2002, Monsun and MDI agreed to the second extension of the maturity date of the note. As consideration for the second extension agreement, MDI issued a three-year warrant to Monsun, entitling the holder to purchase 200,000 shares of common stock of MDI at an exercise price of $0.30 per share. A fair value of $4,110 for the warrant was calculated using the fair value interest rate method and was recorded as additional interest expense during 2002. On April 1, 2002, Monsun and MDI agreed to the third and final extension of the maturity date until July 31, 2002. As consideration for the third extension agreement, MDI issued a five-year warrant to Monsun, entitling the holder to purchase 200,000 shares of common stock of MDI at an exercise price of $0.70 per share, and adjusted the interest rate on unpaid principal to 20% per annum. A fair value of $8,287 for the warrant was calculated using the fair value interest rate method and was recorded as additional interest expense during 2002. In November 2002, MDI issued 200,000 shares of its common stock as a default penalty on the note. A fair value of $42,000 for the shares was calculated using the market price of the common stock on the date the shares were issued and recorded as financing expenses during 2002. MDI made payments against the principal of the note amounting to $117,266 and recorded interest expense, in addition to the amounts mentioned above, of $80,200 during 2002. 12 In January 2003, Monsun initiated a legal action against Peter Gombrich, MDI's then-Chairman, as a personal guarantor on the note, in an attempt to collect the unpaid principal balance of the note. Monsun was successful in obtaining a legal judgment of approximately $675,000 related to the note balance and accrued interest against Mr. Gombrich as personal guarantor. In addition, Monsun was granted an award of approximately $438,000 for attorneys' fees against Peter Gombrich as the personal guarantor. The award for legal fees has been recorded as an accrued expense. (See Note 5 - Accrued Expenses) Those judgments remain unsatisfied. Monsun has not filed suit directly against the Company to recover any amounts due under the note or otherwise. MonoGen, Inc. In October 2004, MDI entered into a settlement agreement with MonoGen, Inc. relating to an arbitration proceeding brought against AccuMed and Oncometrics by MonoGen for alleged breaches in connection with certain license and related agreements among the parties. As part of the settlement, MDI issued a promissory note to MonoGen in the amount of $305,000, payable in an initial installment of $25,000 on November 1, 2004 and monthly installments thereafter of $10,000 until the note is paid in full, and agreed to transfer to MonoGen certain assets. Inasmuch as the assets were not timely transferred, and because the initial $25,000 payment to be made under the note was not paid by its due date, MonoGen delivered a notice of default to the Company and AccuMed in November 2004. If the default asserted in the notice is not cured, there are a number of remedies that may be available to MonoGen under the provisions of the settlement agreement and the note, one of which is the possibility that the full principal amount of the note may be accelerated and declared immediately due and payable. To date, neither MDI nor any related party to the suit has received further notice in regard to the asserted default, although not all of the remedies that may be available to MonoGen in regard to such default would require that further notices be given. Ungaretti & Harris LLP. In March 2005, MDI entered into a settlement agreement related to a judgment entered against the Company and in favor of Ungaretti & Harris LLP in the law firm's suit against MDI for unpaid legal fees. In January 2005, the court had entered summary judgment in favor of Ungaretti & Harris in the amount of $195,500, plus costs of suit. The parties subsequently entered into a settlement agreement in satisfaction of the judgment, whereby MDI promised to pay $150,000 to the law firm, payable in installments of $25,000 commencing March 22, 2005, and with subsequent payments due in ninety day increments until the balance is paid in full. The Company is currently in default on the September 21, 2005 payment due and is in discussions with Ungaretti & Harris. See Note 10 - Legal Proceedings for more information regarding the legal proceedings regarding or giving rise to the above Monsun, Ungaretti & Harris, and MonoGen notes. Defaults. The Company is in breach of a significant majority of its outstanding notes payable, including the Bridge I and Bridge II Convertible Promissory Notes, primarily due to the Company's failure to make principal payments when due. In certain cases, the notes payable require that in order for certain types of events of default to occur, the holder must notify MDI in writing of a declaration of default, at which time a cure period, as specified in each individual note, would commence. There is no guarantee that MDI would be able to cure any existing or future event of default if, or when, the holder provides the required written notice. Other than the Monsun convertible promissory note, the MonoGen note payable, and the note payable to Ungaretti & Harris, which are the subject of legal actions described in Note 10 - Legal Proceedings (certain of which have been settled or are in settlement discussions as discussed herein), MDI has not received any written declarations of default from holders of its outstanding notes payable, although several of such notes do not require written notice of default. For a more detailed discussion of the terms and conditions of certain of the Company's notes payable, see Item 3 in Part II of this Quarterly Report on Form 10-QSB. Carrying Amounts. Management believes it is not practicable to estimate the fair value of the notes payable due to the uncertainty regarding repayment, the possible conversion of amounts due into stock of the Company, and the Company's current financial condition. 13 Note 8. Stockholders' Equity (Deficit) A summary of the Company's preferred stock is as follows:
September 30, December 31, 2005 2004 --------------- --------------- Shares Issued & Shares Issued & Series of Preferred Stock Outstanding Outstanding ----------------------------------------------------- --------------- --------------- (unaudited) Series A convertible ................................ 82,655 82,655 Series B convertible, 10% cumulative dividend ....... 365,106 365,106 Series C convertible, 10% cumulative dividend ....... 245,833 262,833 Series D convertible, 10% cumulative dividend ....... 175,000 175,000 Series E convertible, 10% cumulative dividend ....... 233,598 233,598 --------------- --------------- Total Preferred Stock ......................... 1,102,192 1,119,192 =============== ===============
Convertible Cumulative Preferred Stock Conversions: During the third quarter of fiscal 2005, a holder of Series C Convertible Cumulative Preferred Stock elected to convert 17,000 shares and cumulative dividends into 118,250 unregistered shares of the Company's common stock. Summary of Preferred Stock Terms Series A Convertible Preferred Stock Liquidation Value: $4.50 per share Conversion Price: $10.3034 per share Conversion Rate: 0.4367--Liquidation Value divided by Conversion Price ($4.50/$10.3034) Voting Rights: None Dividends: None Conversion Period: Any time Series B Convertible Preferred Stock Liquidation Value: $4.00 per share Conversion Price: $1.00 per share Conversion Rate: 4.00--Liquidation Value divided by Conversion Price ($4.00/$1.00) Voting Rights: None Dividends: 10%--Quarterly--Commencing March 31, 2001 Conversion Period: Any time Cumulative dividends in arrears at September 30, 2005 were $682,572 Series C Convertible Preferred Stock Liquidation Value: $3.00 per share Conversion Price: $0.60 per share Conversion Rate: 5.00--Liquidation Value divided by Conversion Price ($3.00/$0.60) Voting Rights: None Dividends: 10%--Quarterly--Commencing March 31, 2002 Conversion Period: Any time Cumulative dividends in arrears at September 30, 2005 were $288,585 Series D Convertible Preferred Stock Liquidation Value: $10.00 per share Conversion Price: $1.00 per share Conversion Rate: 10.00--Liquidation Value divided by Conversion Price ($10.00/$1.00) Voting Rights: None Dividends: 10%--Quarterly--Commencing April 30, 2002 Conversion Period: Any time Cumulative dividends in arrears at September 30, 2005 were $728,767 14 Series E Convertible Preferred Stock Liquidation Value: $22.00 per share Conversion Price: $0.80 per share Conversion Rate: 27.50--Liquidation Value divided by Conversion Price ($22.00/$0.80) Voting Rights: Equal in all respects to holders of common shares Dividends: 10%--Quarterly--Commencing May 31, 2002 Conversion Period: Any time Cumulative dividends in arrears at September 30, 2005 were $1,933,341 Issuance of Common Shares for Cash In the third quarter of fiscal 2005, the Company received net aggregate proceeds of $733,500 and issued an aggregate 31,660,000 shares of restricted common stock at $0.025 per share and are reflected in Additional Paid In Capital until such time as such shares are actually issued by the Company's transfer agent and will then be reflected in our Common Stock register and account. Exchange of certain Bridge I, III, IV Convertible Promissory Notes for Common Shares As described in more detail in Note 7, during the third quarter of fiscal 2005, noteholders of certain Bridge I, III and IV Convertible Promissory Notes elected to exchange an aggregate $6,884,000 principal and accrued interest for 42,896,198 unregistered shares of the Company's common stock Note 9. Equity Incentive Plan and Employee Stock Purchase Plan On May 25, 1999, stockholders approved the establishment of the Company's 1999 Equity Incentive Plan (the "Plan") effective as of June 1, 1999. The Plan provides that the Board may grant various forms of equity incentives to directors, employees, and consultants, including but not limited to incentive stock options, non-qualified stock options, stock appreciation rights, and restricted stock awards. Awards under the Plan are exercisable at fair market value determined as of the date of grant in accordance with the terms of the Plan. Awards vest immediately or ratably over periods ranging from two to five years, and expire five to ten years from the date of grant. On May 23, 2000, stockholders approved Amendment No. 1 to the Plan, which increased the number of shares of common stock allocated for use in the Plan from 2,000,000 shares to 3,000,000 shares. On June 21, 2002, stockholders approved a second amendment to the Plan, which increased the number of shares allocated for use in the Plan from 3,000,000 shares to 5,500,000 shares. On July 29, 2004, stockholders approved a third amendment to the Plan, which increased the number of shares for use in the Plan from 5,500,000 to 20,000,000 shares. The Board of Directors has also granted options to purchase the common stock of MDI outside of the Plan. As permitted by SFAS No. 123, MDI currently applies Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" and related interpretations in accounting for options granted to employees under the Plan. No compensation cost was recorded during the nine months ended September 30, 2005 or the year ended December 31, 2004 for options granted to employees, as the exercise prices of such options approximated the fair value of the underlying common stock on the date of the grant. Had stock options been accounted for under the fair value method recommended by SFAS No. 123, the Company's net loss allocated to common shareholders would have been changed to the pro forma amounts indicated below: 15
For the nine months For the three months ended, September 30, ended September 30, 2005 2004 2005 2004 ------- ------- ------- ------- (in thousands except for per share amounts) (unaudited) Net loss applicable to common stockholders as reported ............................... $(2,704) $(6,188) $ (308) $(1,949) Deduct: Total stock-based compensation expense determined under the fair value based method for all awards and forfeitures, net of related taxes ................................... (9) (137) -- 34 ------- ------- ------- ------- Pro forma net loss applicable to common stockholders .................................... $(2,713) $(6,325) $ (308) $(1,915) ======= ======= ======= ======= Basic and diluted loss per share applicable to common stockholders - as reported ............................. $ (.02) $ (.09) $ (.00) $ (.02) ======= ======= ======= ======= Basic and diluted loss per share applicable to common stockholders - pro forma ............................... $ (.02) $ (.09) $ (.00) $ (.02) ======= ======= ======= =======
The fair value for these options was estimated at the date of the grant using a Black-Scholes option pricing model with the following weighted average assumptions: risk-free interest rates of 4.28% and 5.33% for the September 30, 2005 and 2004 periods, respectively; volatility factors of the expected market price of the Company's common stock of 117% and 173%, respectively; and a fair value of the underlying common shares equal to the closing market price of such shares on the date of the grant. The expected life equaled the term of the options or restricted shares. A summary of the Company's stock option activity and related information follows: Weighted Average Exercise Options Price ---------- --------- Outstanding at January 1, 2004 ....................... 3,494,648 Granted .............................................. 2,500,000 $ 0.1540 Forfeited ............................................ (1,046,921) $ 1.0276 ---------- Outstanding at December 31, 2004 ..................... 4,947,727 Granted .............................................. -- Expired .............................................. (438,736) $ 2.6000 Forfeited ............................................ (250,000) $ 0.1400 ---------- Outstanding at September 30, 2005 .................... 4,258,991 ========== Exercisable at September 30, 2005 .................... 3,545,658 $ 0.5845 ========== At the Annual Meeting on May 25, 1999, MDI stockholders also approved the Company's Employee Stock Purchase Plan (the "ESPP"). The ESPP offers employees the opportunity to purchase shares of common stock of MDI through a payroll deduction plan at 85% of the fair market value of such shares at specified enrollment measurement dates. The aggregate number of shares available for purchase under the ESPP is 200,000. In December 2004, FASB issued Statement of Financial Accounting Standards No. 123(revised), "Share-Based Payment". SFAS No. 123(R) establishes accounting standards for transactions in which a company exchanges its equity instruments for goods or services. In particular, this statement will require companies to record compensation expense for all share-based payments, such as employee stock options, at fair market value. This statement is effective for the Company as of the beginning of the first annual reporting period that begins after December 15, 2005. Adoption of this statement is not expected to have a material impact on the Company's consolidated financial position or results of operations. Note 10. Legal Proceedings Included below is a summary of legal proceedings involving the Company that were either initiated in the fiscal quarter ended September 30, 2005 or with respect to which a material development occurred during such quarter. For a more detailed discussion of all legal proceedings involving the Company and other information on previous developments, see the Company's Annual Report on Form 10-KSB, as amended, for the fiscal year ended December 31, 2004 and quarterly reports for the quarters ended March 31, 2005 and June 30, 2005. 16 Settled Since June 30, 2005 The Cleveland Clinic Foundation. On March 28, 2003, The Cleveland Clinic Foundation filed suit against MDI (U.S. District Court for the Northern District of Ohio, Eastern Division (Case No. 1:03CV056)) seeking approximately $315,000 for certain clinical trial work conducted by the Foundation in the Peoples Republic of China on behalf of MDI. On December 8, 2003, a default judgment in the amount of $260,000 was entered against MDI. In June 2005, the parties executed a settlement agreement and mutual release in satisfaction of such judgment, pursuant to which MDI agreed to pay the Foundation an aggregate $100,000, assuming certain conditions were met. Once final payment under the settlement agreement had been made, the Foundation agreed to release MDI from any and all claims, demands, rights or causes of action. As of September 30, 2005, MDI had made final payment of $85,000 in full satisfaction of the settlement agreement and requested that the Foundation take all steps necessary to file a satisfaction of judgment. As of September 30, 2005, MDI had recorded no liability relating to this case. Eric Gombrich. On May 19, 2004, former MDI officer Eric Gombrich filed suit against MDI, Denis M. O'Donnell, M.D., Peter Gombrich, Dennis Bergquist, and Michael Brodeur (all of whom are no longer officers or directors of the Company) in the Circuit Court of Cook County, Illinois (04 L 05661). Mr. Gombrich claimed that MDI breached a written employment contract and that it owed him $631,258 (plus interest) and 300,000 shares of MDI stock. In October 2005, MDI entered into a settlement agreement with Mr. Gombrich pursuant to which MDI agreed to pay Mr. Gombrich an aggregate $116,000 in three scheduled payments (one of which has already been tendered) and issue him a warrant to purchase 300,000 shares of the Company's common stock at an exercise price of $.10 per share exercisable until July 31, 2009. The parties also agreed to a release and covenant not to sue for any and all claims arising out of Mr. Gombrich's employment. Pursuant to the settlement, the case against MDI was dismissed on November 8, 2005. As of September 30, 2005, MDI had recorded a liability in the amount of $148,000 relating to this case. Esoterix, Inc. Esoterix, Inc. made a claim against MDI for $19,725 arising from a laboratory services agreement that it maintains MDI breached. In March 2005, Esoterix filed suit against MDI to collect this claim in the Circuit Court of Cook County, Illinois (05 M1 116482). MDI entered into a settlement agreement with Esoterix in October 2005 pursuant to which MDI agreed to pay Esoterix $13,000 in full satisfaction of its claims. The case was dismissed following payment on October 11, 2005. The parties also agreed to a mutual release of all claims. As of September 30, 2005, MDI had recorded a liability in the amount of $13,000 relating to this case. Kanan, Corbin, Schupak & Aronow, Inc. On August 12, 2004, Kanan, Corbin, Schupak & Aronow, Inc. ("KCSA") filed suit against AccuMed International, Inc. f/d/b/a Molecular Diagnostics, Inc., in the Circuit Court of Cook County, Illinois (04 L 9109), seeking $59,678, plus interest and court costs, for services provided. The parties agreed to a settlement in November 2005, although no formal settlement agreement has been executed. Assuming the parties satisfy all terms of the settlement, the case will be dismissed. As of September 30, 2005, MDI had recorded $66,000 as a liability for this matter. The Lash Group, Inc. On June 10, 2004, The Lash Group, Inc., a healthcare consulting firm, filed a lawsuit against the Company in the General Court of Justice, Superior Court Division, in Mecklenburg County, North Carolina (04 CVS 10367). The Lash Group sought approximately $94,000, plus interest, attorney fees, and court costs, for the alleged breach of an agreement, with respect to which Peter Gombrich, our former Chairman and Chief Executive Officer, and MDI are sought to be held primarily liable. In October 2005, MDI entered into a settlement agreement with The Lash Group and a voluntary dismissal has been filed. Pursuant to the settlement agreement, MDI must make equal three payments totaling $100,000, beginning December 2005 and following in February and March 2006 until paid in full. If MDI fails to make full payment, it has agreed to the entry of a judgment against it in the amount of $147,866, less credit for any payments made. As of September 30, 2005, MDI had recorded a liability in the amount of $97,000 relating to this case. Ungaretti & Harris LLP. On May 31, 2004, the law firm Ungaretti & Harris LLP filed an amended complaint against MDI in the Circuit Court of Cook County, Illinois (04 L 1101), to collect fees for services rendered prior to December 31, 2003. In January 2005, the court entered summary judgment in favor of Ungaretti & Harris and against MDI in the amount of $195,500, plus costs of suit. The parties subsequently entered into a settlement agreement to satisfy the judgment. Ungaretti & Harris declared the settlement agreement in default for MDI's failure to make the second payment on June 21, 2005. The parties have since modified the settlement agreement, and MDI cured the claimed default, although it is now currently in default on the September 21, 2005 payment due. The parties are in discussions regarding this default. As of September 30, 2005, MDI had recorded a liability in the amount of $148,000 relating to this case. 17 Pending as of September 30, 2005 Medical College of Georgia Research Institute, Inc. On November 18, 2003, the Medical College of Georgia Research Institute, Inc. filed suit against MDI in the Superior Court of Richmond County, Georgia (Case No. 2003-RCCV-1211) to collect amounts allegedly due pursuant to an agreement to provide a clinical study for MDI. Georgia Research Institute claimed that the principal amount of the obligation due from MDI was approximately $86,700, but sought to collect approximately $315,300 pursuant to an interest provision of 10% per month. On October 27, 2004, the court entered summary judgment in favor of Georgia Research Institute and against MDI in the amount of $68,404. As of September 30, 2005, MDI had recorded a liability in the amount of $115,000 relating to this case. Peter Gombrich. On April 25, 2005, former MDI officer Peter Gombrich filed suit against MDI and MDI's former Chief Executive Officer Denis M. O'Donnell, M.D. in the Circuit Court of Cook County, Illinois (05 L 4543). Mr. Gombrich claims that MDI breached a written employment contract and that it owes him in excess of $849,500 (plus interest and attorneys' fees). Mr. Gombrich also alleged a claim against MDI for contribution and indemnification regarding agreements he signed as a personal guarantor for certain alleged MDI obligations. MDI filed a motion to compel the case to arbitration, consistent with Mr. Gombrich's employment agreement. This motion was granted on August 9, 2005. At this time, MDI has filed its answer, affirmative defenses, and has asserted numerous counterclaims against Mr. Gombrich. The arbitrator set a final hearing date in early February 2006. MDI intends to vigorously defend this proceeding. Management cannot reasonably estimate the liability, if any, related to this matter or the likelihood of an unfavorable settlement at this time. Diamics LLC. On October 21, 2005, the Company filed suit against Diamics LLC and related parties in the Federal District Court, Northern District of California (C05-4282). Diamics was formed by Peter Gombrich, MDI's former Chairman of the Board and CEO. MDI alleges that Mr. Gombrich and a former employee misappropriated MDI's proprietary information, trade secrets and patented products, and the suit charges Diamics with misappropriation of trade secrets, unfair business practices, conversion, and patent and copyright infringement. The suit seeks injunctive relief and damages in excess of $30,000,000. The complaint in MDI's case has been served on Diamics, and MDI is awaiting the defendants' answer. MDI's suit against Diamics was in part a response to a suit filed by Diamics against MDI on June 21, 2005 in the Federal District Court, Northern District of California (C05-02549). The complaint in that suit seeks declaratory judgment of no misappropriation, conversion, libel or unjust enrichment, and requests that the court enter judgment as follows: declaration that Diamics has not directly or indirectly misappropriated MDI's trade secrets, confidential and proprietary intellectual property, reputation, or goodwill; declaration that Diamics has not converted MDI's confidential and proprietary intellectual property; declaration that Diamics has not been unjustly enriched; and for an order enjoining MDI and its officers, agents, servants, and employees from asserting that Diamics or its employees engaged in the above mentioned conduct. Although the abovementioned complaint was filed in June, it was amended on October 12, 2005 and allegedly served on October 13, 2005. MDI has yet to confirm whether the complaint was served as alleged by Diamics. In the event the complaint is properly served, MDI intends to vigorously defend this action. Management cannot reasonably estimate the liability, if any, related to this matter or the likelihood of an unfavorable settlement. Accordingly, no liability related to this matter has been accrued or recorded to date. Miscellaneous Creditors. Several current or former unsecured creditors have made claims against MDI to collect past due amounts for goods and services. MDI has recorded the amounts due in its records and is attempting to settle these claims. Ketchum Public Relations. MDI settled a $72,000 claim by Ketchum Public Relations. No litigation was ever filed by Ketchum. MDI paid $10,000 in full payment and satisfaction of the balance due in September 2005, and all claims by Ketchum against MDI were released as of September 26, 2005. 18 Item 2. Management's Discussion and Analysis or Plan of Operation Forward-Looking Statements Certain statements contained in this discussion and analysis that are not related to historical results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are predictive, that depend upon or refer to future events or conditions, or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," "hopes," and similar expressions constitute forward-looking statements. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), business strategies or prospects, or possible future actions by us are also forward-looking statements. These forward-looking statements are based on beliefs of our management as well as current expectations, projections, assumptions and information currently available to the Company and are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated or implied by such forward-looking statements. These risks are described more fully in our most recent Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004 under the caption "Risk Factors" and in subsequent reports filed with the Securities and Exchange Commission. Should one or more of those risks or uncertainties materialize or should underlying expectations, projections and assumptions prove incorrect, actual results may vary materially from those described. Those events and uncertainties are difficult to predict accurately and many are beyond our control. We assume no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date of these statements except as specifically required by law. Accordingly, past results and trends should not be used to anticipate future results or trends. Overview of Molecular Diagnostics, Inc. Molecular Diagnostics, Inc., formerly Ampersand Medical Corporation, is a biomolecular diagnostics company focused on the design, development and commercialization of cost-effective screening systems to assist in the early detection of cancer. MDI has currently curtailed its operations and expects to resume such operations only when additional capital has been obtained by the Company. The InPath System and related products are intended to detect cancer and cancer-related diseases, and may be used in a laboratory, clinic or doctor's office. MDI's goal is to utilize recent research regarding the human genome and related proteins, which form the foundation of cell biology and the human body, as a base to develop screening and diagnostic testing products for cancer and cancer-related diseases. We believe that the success of these products will improve patient care through more accurate test performance, wider product availability and more cost effective service delivery. We were developing, and plan to continue developing upon obtaining additional capital, an initial series of products to address these criteria including sample collection devices, chemical and biological tests, and analysis instruments and related software. Our strategy is to develop products through internal development processes, strategic partnerships, licenses and acquisitions of companies. This strategy has required and will continue to require additional capital. As a result, we will incur substantial operating losses until we are able to successfully market some, or all, of our products. We have designed and manufactured the AcCell(TM) computer-aided automated microscopy instrument and the AcCell Savant(TM), an instrument that includes an AcCell instrument and software and which collects quantitative cellular information used in support of a diagnostic process. These instruments have been sold to laboratories and medical diagnostic companies for use in the customers' proprietary applications, although based on a settlement entered into with MonoGen, Inc. in 2004, we have transferred certain patents and intellectual property rights for the AcCell instrument to MonoGen. MDI also entered into a settlement agreement with Dr. Bruce Patterson and Invirion, Inc. over the validity of a certain technology license. MDI agreed to the termination and return of the license to Dr. Patterson and Invirion. The Company now is focused on marketing a new, fully-integrated workstation - the Automated Image Proteomic System or "AIPS(TM)" - based on updated technology. Assuming sufficient funding, we expect that the new platform will be marketed through a distribution partner and, in certain instances, will be placed in a customer facility on a fee-for-use basis. Nearly all of our reported revenue to date has been from the sale of AcCell products and services and from a former subsidiary's discontinued operations. 19 The Company has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement MDI's business plan and develop, manufacture and market its products. These circumstances raise substantial doubt about MDI's ability to continue as a going concern. Implementation of the Company's plans and its ability to continue as a going concern depend upon its securing substantial additional financing. During the first nine months of 2005, MDI raised net proceeds of $1,377,762 through the sale of common stock. Management's plans for the remainder of fiscal 2005 include substantial efforts to obtain additional capital. During the quarter ended September 30, 2005, the Company was unable to obtain adequate financing or generate profitable sales revenues, and was forced to curtail its product development and other activities. If the Company continues to be unable to obtain adequate financing to fund operations, it will be forced to cease operations and may seek bankruptcy protection. Recent Developments The Company elected during the third quarter of fiscal 2005 to replace the former CEO and Chairman with Dr. David Weissberg and the former CFO with Robert McCullough. Both Dr. Weissberg and Mr. McCullough are substantial shareholders of the Company's common stock. The Company filed current reports on Form 8-K for both appointees during the third quarter of fiscal 2005, which can be referenced and reviewed for further information about these individuals. Critical Accounting Policies and Changes to Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. There have been no material changes in our critical accounting policies or critical accounting estimates since December 31, 2004, nor have we adopted any accounting policy that has or will have a material impact on our consolidated financial statements. For further discussion of our accounting policies see Note 3 - Summary of Significant Accounting Principles in the Notes to Consolidated Financial Statements included in this Quarterly Report on Form 10-QSB, as well as our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004. Results of Operations The following discussion and analysis should be read in conjunction with our unaudited consolidated financial statements presented in Part I, Item 1 of this Quarterly Report, and our audited consolidated financial statements and notes thereto, and our Management's Discussion and Analysis contained in our Annual Report on Form 10-KSB for the year ended December 31, 2004. Three Months Ended September 30, 2005 as compared to Three Months Ended September 30, 2004 Revenue Revenues for the three months ended September 30, 2005 decreased $17,000, or 41.5%, to $24,000 from revenues of $41,000 for the same period in 2004. This decrease was the result of a reduction in revenue from the sale of our slide-based installed systems. 20 Costs and Expenses Cost of Goods Sold Cost of goods sold remained at zero for the quarter ended September 30, 2005 similar to the same period in 2004, since no AcCell instruments were sold during either period. Research and Development We have devoted a substantial amount of our resources to research and development ("R&D") related to new products, including markers, tests, instruments and software applications, as well as modifications to and refinements of our existing products. For the quarter ended September 30, 2005, our R&D expenses were $31,000, a decrease of $200,000, or 86.6%, over the same period in 2004. This decrease was the result of reduced operating capacity due to capital and liquidity constraints. This reduction has led to delays in the finalization of the development, completion of clinical trial validation, Food and Drug Administration submissions and approval, market introduction, and the sale of some of our products. R&D expenses have typically consisted of costs related to specific development programs with scientists and researchers at universities and hospitals; full scale device development contracts begun during 1999 with industrial design and manufacturing companies covering the disposable and instrument components of the InPath System; payments to medical and engineering consultants for advice related to the design and development of our products and their potential uses in the medical technology marketplace; and payroll related costs for in-house engineering, scientific, laboratory, software development and research management staff. Selling, General and Administrative For the quarter ended September 30, 2005, selling, general and administrative expenses ("SG&A") were a positive $55,000, a decrease of $1,171,000, or over 100.0%, over expenses of $1,116,000 for the same period in 2004. This decrease included a reduction of $630,000 in legal and professional fees, $103,000 in consulting fees, $106,000 in financing costs, and $252,000 in other general and administrative costs. The decrease also had an additional period difference of $80,000 in restructured settlement income. Restructuring settlements reflect the difference between the actual settlement amounts for various litigation and creditor payment matters and the amounts originally recorded on the Company's financial statement as the amount due. Settlement amounts were less than amounts originally recorded in recognition of the Company's financial condition. Significant components of SG&A are compensation costs for executive, sales and administrative personnel, professional fees primarily related to legal and accounting services, travel costs, fees for public and/or investor relations services, insurance premiums, facilities and office expenses, marketing-related costs, and amortization/depreciation charges (net of restructuring settlement). Other Income and Expense Interest Expense Interest expense, including interest expense to related parties, decreased $285,000 for the quarter ended September 30, 2005 to $126,000, a decrease of 69.3% over the same period of 2004. Bridge I, II, III, IV, and related party Convertible Promissory Notes in principal amounts totaled $6,356,000 and $6,672,000 for the fiscal quarters ended September 30, 2005 and 2004, respectively. The interest expense decrease results from the decrease cumulative effect of compounding interest on the unpaid Bridge I, II, III, IV and Monsun Convertible Promissory Notes offset by the $328,000 gain on waived Bridge IV Convertible Promissory Notes.. Other Income Other income remained at zero for the quarter ended September 30, 2005 similar to the same period in 2004. 21 Net Loss The net loss for the three-month period ended September 30, 2005 before preferred dividends totaled $78,000, compared with $1,717,000 for the same period in 2004, a decrease of $1,639,000 or 95.5%. The decrease was primarily the result of reduced operating capacity due to capital and liquidity constraints. The net loss applicable to common stockholders for the three months ended September 30, 2005 was $308,000, or $0.00 per share, on 118,669,134 weighted average common shares outstanding. This compared with the net loss applicable to common stockholders for the three-month period ended September 30, 2004 of $1,949,000, or $0.02 per share, on 83,374,666 weighted average common shares outstanding. Cumulative dividends on the Company's outstanding Series B, Series C, Series D and Series E convertible preferred stock totaled $230,000 for the quarter ended September 30, 2005, compared with $232,000 for the same period in 2004. Nine Months Ended September 30, 2005 as compared to Nine Months Ended September 30, 2004 Revenues Revenues for the nine months ended September 30, 2005 decreased $102,000, or 52.3%, to $93,000 from revenues of $195,000 for the same period in 2004. This decrease primarily was the result of decreases in the sales of AccuMed-related products and services. A table describing the decrease is provided below: Nine months ended 9/30/05 9/30/04 Decrease ---------------------- ------- -------- --------- Slide-based revenue $93,000 $146,000 $ (53,000) AcCell instrument sale -- 49,000 (49,000) ------- -------- --------- Total Revenue $93,000 $195,000 $(102,000) ======= ======== ========= Costs and Expenses Cost of Goods Sold Cost of goods sold for the nine months ended September 30, 2005 were zero, a decrease of $25,000, or 100%, over the same period in 2004. The cost of goods sold amount reported in 2004 is related to the shipment of two automated microscopy systems during the nine months ended September 30, 2004. Research and Development As noted above, we have devoted a substantial amount of our resources to R&D related to new products, including markers, tests, instruments and software applications, as well as modifications and refinements of our existing products. For the nine months ended September 30, 2005, our R&D expenses were $128,000, a decrease of $588,000, or 82.1%, over the same period in 2004. This decrease was the result of reduced operating capacity due to capital and liquidity constraints. This reduction has led to delays in the finalization of the development, completion of clinical trial validation, Food and Drug Administration submissions and approval, market introduction, and the sale of some of our products. Selling, General and Administrative For the nine months ended September 30, 2005, SG&A expenses were $1,047,000, a decrease of $2,207,000, or 67.8%, over expenses of $3,254,000 for the same period in 2004. This decrease included a reduction of $1,107,000 in financing costs, $860,000 in legal and professional fees, $231,000 in consulting fees, $212,000 in FDA clinical trials costs, $201,000 in investor relations expenditures and $449,000 in other general and administrative costs. These decreases were offset by period differences of $758,000 in restructuring settlement income and a $95,000 net gain on sale of fixed assets. Restructuring settlements reflect the difference between the actual settlement amounts for various litigation and creditor payment matters and the amounts originally recorded on the Company's financial statement as the amount due. Settlement amounts were less than amounts originally recorded in recognition of the Company's financial condition. 22 Other Income and Expense Interest Expense Interest expense, including interest expense to related parties, decreased $657,000 for the nine-month period ended September 30, 2005 to $939,000, a decrease of 41.2% over the same period of 2004. Bridge I, II, III and IV and related party convertible promissory notes in principal amounts totaled $2,665,000 and $6,224,000 for the periods ended September 30, 2005 and 2004, respectively. The decrease in interest expense was largely due to Bridge I, II, III and IV note conversions to the Company's common stock during the nine-month period ended September 30, 2005, offset by a period difference of $328,000 in gain on waived interest on Bridge IV Convertible Promissory Notes. Other Income/Expense Other expense decreased $10,000 to zero for the nine-month period ended September 30, 2005 over the same period of 2004. The $10,000 decrease resulted from residual Samba operations foreign currency translation loss, which was liquidated in bankruptcy in December 2003. Net Loss The net loss for the nine-month period ended September 30, 2005 before preferred dividends totaled $2,021,000, compared with $5,386,000 for the same period in 2004, a decrease of $3,365,000 or 62.5%. The decrease was primarily the result of reduced operating capacity due to capital and liquidity constraints. The combined net loss applicable to common stockholders for the nine months ended September 30, 2005 of $2,704,000, or $0.02 per share, on 111,137,400 weighted average common shares outstanding compared with the net loss and net loss available to common stockholders for the nine-month period ended September 30, 2004 of $6,188,000, or $0.09 per share, on 71,054,095 weighted average common shares outstanding. Cumulative dividends on the outstanding Series B, Series C, Series D and Series E convertible preferred stock totaled $683,000 for the nine-month period ended September 30, 2005, compared with $802,000 for the same period in 2004. The weighted average shares outstanding during the nine months ended September 30, 2005 include the shares issued or issuable upon conversion of Series B, Series C, and Series E convertible preferred stock during the period, and the conversion of Bridge I, II, III and IV Convertible Promissory Notes. The Bridge I, II, III and IV note conversions resulted in the issuance of an aggregate 42,896,198 shares of common stock; the Series B, C and E convertible preferred stock conversions resulted in the issuance of an aggregate 118,260 shares of common stock. Liquidity and Capital Resources Research and development, clinical trials and other studies of the components of our InPath System and AIPS workstation, conversions from designs and prototypes into product manufacturing, initial sales and marketing efforts, medical consultants and advisors, administrative, professional and executive personnel fees are and will continue to be the principal basis for our cash requirements. We have provided operating funds for the business since its inception through private offerings of debt and equity to limited numbers of U.S. and foreign accredited investors. We will be required to make additional offerings in the future to support the operations of the business until some or all of our products are introduced into the market. We used $1,227,000 and $3,543,000 for the nine months ended September 30, 2005 and 2004, respectively, in operating activities. We experienced severe liquidity problems during the nine months ended September 30, 2005. As a result, we were forced to cut staff and reduce our operations to a minimum level. Officers refrained from drawing salaries during portions of the first, second and third quarters of 2005 in order to reduce demands on our limited cash position. We were able to raise funds through the sale of common stock during the quarter ended September 30, 2005, although the proceeds of the common stock offerings were used to satisfy certain obligations coming due as well as for the payment of a limited amount of current operational expenses. The Company did generate a limited amount of slide-based revenue liquidity during the nine months ended September 30, 2005. At September 30, 2005, we had $130,000 cash on hand, an increase of $119,000 over cash on hand at December 31, 2004 of $11,000. Although we increased our cash on hand, our cash position was offset by a decrease in our loss from operations and our inability to raise sufficient new capital due to very unfavorable conditions in financing markets, both public and private, for small life sciences companies such as ours. We were unable to raise sufficient funds during the nine months ended September 30, 2005 in order to maintain adequate cash reserves and to meet the ongoing operational needs of the business. 23 We incurred $27,000 in capital expenditures during the first nine months of 2005 versus capital expenditures of $187,000 for the first nine months of 2004, a decrease of 85.6%. Capital expenditures are defined as disbursements for laboratory equipment, leasehold improvements, software, and furniture/fixtures with a purchase price in excess of $1,000 per item and useful life in excess of one year. MDI is striving to keep capital expenditures to a minimum due to capital and liquidity constraints, and the Company has no plans for material commitments for capital expenditures in the near-term. Our operations have been, and will continue to be, dependent upon management's ability to raise operating capital in the form of debt or equity. We have incurred significant operating losses since inception of the business. We expect that significant on-going operating expenditures will be necessary to successfully implement our business plan and develop, manufacture and market our products. These circumstances raise substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to obtain additional capital to meet our current operating needs or to complete pending or contemplated licenses or acquisitions of technologies. During the nine months ended September 30, 2005, the Company was unable to raise adequate capital or generate profitable sales revenues, and was forced to curtail its product development and other activities. If the Company continues to be unable to obtain adequate financing to fund operations, it will be forced to cease operations and may seek bankruptcy protection. Off-Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements. Item 3. Controls and Procedures Evaluation of Disclosure Controls and Procedures Our chief executive officer and chief financial officer have reviewed and evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this quarterly report. Based on that review and evaluation, our chief executive officer and chief financial officer have concluded that our current disclosure controls and procedures, as designed and implemented, are effective to ensure that such officers are provided with information relating to the Company required to be disclosed in the reports filed or submitted by MDI under the Exchange Act and that such information is recorded, processed, summarized and reported within the time periods specified. Changes in Internal Control over Financial Reporting During the quarter to which this report relates, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Part II. Other Information Item 1. Legal Proceedings See Note 10 - Legal Proceedings in the Notes to Consolidated Financial Statements included herein for a discussion of the most recent events regarding the Company's legal proceedings, which information is incorporated herein by reference. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Unregistered Sales of Equity Securities Common Stock. In the third quarter of fiscal 2005, the Company received net aggregate proceeds of $733,500 from accredited investors in exchange for 31,660,000 unregistered shares of common stock at $0.025 per share. 24 MDI issues securities in reliance on the safe harbor and exemptions from registration provided under Rule 506 of Regulation D and/or Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offerings and sales or issuances were made to a limited number of persons, all of whom were accredited investors, and transfer was restricted by the Company in accordance with the requirements of applicable law. In addition to representations by the above-referenced persons, the Company has made independent determinations that all of the investors were accredited or sophisticated investors, that they were capable of analyzing the merits and risks of their investment, and that they understood the speculative nature of their investment. Furthermore, these investors were provided with access to MDI's SEC filings. Company Repurchases of Securities During the third quarter of fiscal 2005, neither the Company nor any affiliated purchaser of the Company purchased equity securities of MDI. Item 3. Defaults upon Senior Securities As of September 30, 2005, MDI was in breach of the following of its notes payable. For more discussion regarding certain of these notes, see Note 7 - Notes Payable and Note 10 - Legal Proceedings in the Notes to Consolidated Financial Statements included in this Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005. Bridge I. The Bridge I Convertible Promissory Notes were originally due July 30, 2002, which maturity date was extended until December 31, 2002 by offer of the Company. Each Bridge I noteholder has the option, upon an event of default, to declare the unpaid principal balance and all accrued interest immediately due and payable upon written notice of default and demand. The Company, upon such notice, is given five days to cure such default. The Bridge I notes define event of default as: (i) the Company's failure to make any payment of principal, interest or other charges on or before the date due; (ii) the Company's breach of any agreement or covenant contained in the note or any document or instrument relating to the indebtedness evidenced by the note; or (iii) dissolution, liquidation or termination of the Company. The Bridge I notes provide that upon the declaration of a default, the balance of the principal remaining unpaid, interest accrued thereon and all other costs and fees shall bear interest at the rate of 18% per annum from the date of default. The Company is also obligated to pay all costs of collection, including reasonable attorneys' fees. As of September 30, 2005, MDI had not received a written declaration of default from the holder of any outstanding Bridge I note. As of September 30, 2005, and after note holders elected to convert $250,000 principal and accrued interest, MDI had recorded principal and interest outstanding on the Bridge I notes of $500,000 and $175,070, respectively. Bridge II. The Bridge II Convertible Promissory notes were originally due July 31, 2003, which maturity date was extended until July 31, 2004 by offer of the Company. The Bridge II notes provide that upon the declaration of a default under the notes, the balance of the principal remaining unpaid, unpaid accrued interest and all other costs and fees shall bear interest at the rate of 15% per annum from the date of default. In addition, in the event of default, the Company and all other parties liable on the notes agreed to pay all costs of collection, including reasonable attorneys' fees. The events constituting an event of default under the Bridge II notes are those events of default specified in the Security Agreement entered into in connection with the Bridge II notes offering, and Bridge II noteholders have all of the rights granted to them under such Security Agreement as well as the Indenture and Collateral Sharing Agreement executed by the parties. The Security Agreement provides that the occurrence of any of the following would constitute an event of default under the Bridge II notes: (i) MDI fails to pay principal or interest on the maturity date; (ii) MDI fails to perform any of its other covenants under the Security Agreement, the notes, or the Indenture that are material to the debtor or the rights of any Bridge II noteholder and such failure continues for 10 days after receipt of written notice thereof; (iii) MDI admits in writing its inability to pay its debts generally as they become due, or makes an assignment for the benefit of creditors or files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other laws for the relief of or relating to debtors; or (iv) an involuntary petition is filed under any bankruptcy or insolvency statute against MDI or a custodian, receiver or trustee is appointed to take possession of any property or assets of the debtor (unless the petition or appointment has been set aside or withdrawn or ceases to be in effect within 30 days from the date of said filing or appointment). 25 Upon the occurrence of any event of default arising from a payment default or covenant default, the Security Agreement provides that the Bridge II noteholders may authorize the declaration of all amounts due from MDI immediately due and payable without notice or demand of any kind. Upon the occurrence of any default arising from insolvency or bankruptcy, all amounts due from MDI automatically and immediately become due and payable without any action on the part of the noteholders or otherwise. The covenants of MDI, as debtor, agreed to by the Company and set forth in the Security Agreement include but are not limited to: (i) not changing its name, jurisdiction or organization or legal structure without consent; (ii) taking reasonable actions to maintain, preserve and defend the collateral under the Security Agreement and executing such documents as may be required to perfect any security interest in such collateral; (iii) after the occurrence of an event of default, providing evidence of ownership of the collateral upon request; (iv) keeping at its office adequate records concerning the collateral; (v) making entries upon its financial statements and books and records to disclose the security interest in the collateral; (vi) providing financial statements and information as reasonably requested; (vii) immediately providing notice of material loss or depreciation in the value of the collateral or any event which is or would become an event of default; and (viii) not selling, transferring, or disposing of, or except in the ordinary course of business or as permitted, pledging, mortgaging, granting a security interest in or otherwise encumbering the collateral or any of MDI's assets. The secured party/collateral agent under the Bridge II notes offering documents has the option (but not the duty), during the continuance of an event of default, to perform any agreement of MDI that the Company failed to perform, and take any action he deems reasonably necessary or desirable for the preservation of the collateral and the secured party's interest therein. The secured party's rights upon the continuance of an event of default also include the taking of any action to realize upon the collateral (including any sale or other disposition at any private or public sale for cash or credit), the discharge of taxes, liens, security interests and other encumbrances levied upon the collateral, and the discharge or keeping current of any of MDI's obligations having any effect on the collateral. The noteholders also authorized the secured party/collateral agent to demand or sue for all monies due with respect to the collateral and commence, file, prosecute and defend any claim or proceeding related to the collateral. As of September 30, 2005, MDI was not aware of any noteholders or group of noteholders having authorized a declaration of default of any outstanding Bridge II notes. As of September 30, 2005, MDI had recorded principal and interest outstanding on the Bridge II notes of $1,300,000 and $545,085, respectively. Monsun AS. The Monsun AS note was originally due November 1, 2000, but the parties agreed to three extensions of the maturity date, with July 31, 2002 as the final maturity date. Pursuant to the third and final maturity extension agreement between the parties, each of the following occurrences constituted an event of default under the Monsun note: (i) failure to pay when due specified interest; (ii) failure to pay when due all unpaid principal and other interest due by July 31, 2002; (iii) the material breach or failure to observe any provision of the extension agreement; or (iv) the insolvency or general failure of MDI to pay its debts as they become due, MDI's admission in writing of its inability to pay debts generally, MDI's making a general assignment for the benefit of creditors, the institution of any proceeding by or against MDI seeking an order for relief or to adjudicate MDI bankrupt or insolvent, or the institution of any other proceeding against MDI under any law relating to bankruptcy, insolvency or relief of debtors or seeking the appointment of a receiver, trustee or similar official for MDI or any substantial part of MDI's assets. Upon the occurrence of an event of default, the entire principal amount outstanding under the Monsun note, including any unpaid and accrued interest, becomes at once due and payable without presentment, demand or protest or any other requirements of any kind. The note also provided that at all times after July 31, 2002, the note would begin to accrue interest at the rate of 20% per annum to the extent there was unpaid principal or accrued and unpaid interest. Following the failure to pay principal and interest when due, Monsun initiated legal action against Peter Gombrich, MDI's then-Chairman, as a personal guarantor on the Monsun note in January 2003. Monsun was successful in obtaining a legal judgment of approximately $675,000 related to the note balance and accrued interest against Mr. Gombrich as personal guarantor. In addition, Monsun was granted an award of approximately $438,000 for attorney's fees against Peter Gombrich as the personal guarantor. These judgments remain unsatisfied. 26 As of September 30, 2005, MDI had recorded principal and accrued interest on the Monsun note and the legal fee award outstanding of $907,000 and $438,000, respectively. As of September 30, 2005, Monsun had not initiated any legal action against MDI directly to collect any amounts due or otherwise. MonoGen, Inc. The MonoGen, Inc. note was the result of a settlement agreement reached in October 2004 as discussed in Note 7 - Notes Payable in the Notes to Consolidated Financial Statements included in this Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005. The MonoGen note provides that in the event of (i) a failure by MDI to pay any amount due under the note within 10 days of the date due, (ii) a breach by MDI of any covenant, obligation, representation or warranty made in the note, the parties' Settlement Agreement, or a License Agreement entered into in connection with the settlement, or (iii) MDI becoming the subject of bankruptcy or other insolvency proceedings, then, in any such event, in addition to all rights MonoGen may have under the Settlement Agreement, any related agreement or any applicable law, MonoGen may at its option and without notice or demand declare any or all of MDI's obligations and indebtedness under the note immediately due and payable. At such time, any unpaid principal and unpaid accrued interest would become due and payable, together with interest thereafter at a default rate of 14% until the note is paid in full. In addition, MDI would be liable for the costs and expenses of collection, including reasonable attorneys' fees and legal expenses. MDI covenanted in the note that it would not, directly or indirectly, declare or pay any dividends or make any loans or advances to, or guarantee or otherwise become liable upon the obligation of, any person or entity controlling or affiliated with the Company. MDI covenanted in the Settlement Agreement to assign certain intellectual property and deliver certain assets to MonoGen. The Company also agreed that it would not amend or modify specified agreements relating to the technology subject to the settlement and would not enter into new agreements without MonoGen's consent. As discussed in Note 7 - Notes Payable, inasmuch as the assets were not timely transferred, and because the initial $25,000 payment to be made under the MonoGen note was not paid by its due date, MonoGen delivered a notice of default to the Company and AccuMed in November 2004, whichMDI has not cured. To date, neither MDI nor any related party to the suit has received further notice in regard to the asserted default, although not all of the remedies that may be available to MonoGen in regard to such default would require that further notices be given. As of September 30, 2005, MDI had recorded principal and accrued interest outstanding of $305,000 and $39,875, respectively, with respect to the MonoGen note. Ungaretti & Harris. In March 2005, MDI entered into a settlement agreement related to a judgment entered against the Company and in favor of Ungaretti & Harris LLP in the law firm's suit against MDI for unpaid legal fees. In January 2005, the court had entered summary judgment in favor of Ungaretti & Harris in the amount of $195,500, plus costs of suit. The parties subsequently entered into a settlement agreement in satisfaction of the judgment, whereby MDI promised to pay $150,000 to the law firm, payable in installments of $25,000 commencing March 22, 2005, with subsequent payments due in 90 day increments until the balance was paid in full. The settlement agreement also provided that should any payment be more than 15 days late, Ungaretti & Harris would be entitled to notify the Company of default and declare the settlement agreement terminated; if the settlement agreement was terminated because of such payment default, the entire balance of the judgment, interest and costs would become the obligation of the Company, less any payments made. As discussed in Note 7 - Notes Payable, MDI is currently in default on the September 21, 2005 payment due and is in discussions with Ungaretti & Harris. In the event that payment is not made or a resolution is not reached with Ungaretti & Harris, the entire balance of the judgment, interest and costs would be due and payable as noted above. In addition, Ungaretti & Harris has a secured position in all assets of the Company as part of the Bridge II collateral agreement. As of September 30, 2005, MDI had recorded principal and accrued interest outstanding of $127,000 and $21,376, respectively, with respect to the $150,000 Ungaretti & Harris note. Ernst & Young LLP. The maturity date of the Ernst & Young note was December 31, 2003. Peter Gombrich, MDI's former officer and director, is a personal guarantor on such note and is obligated to make payment when the Company defaults on the note, Ernst & Young has given written notice of such default to the Company, and the Company fails to cure within 30 days of such notice. 27 The note provides only that in the event the principal amount of $30,800 is not paid by the maturity date, the Company would be obligated to pay interest at the rate of 12% per annum, or the maximum legally enforceable rate (whichever is less), on any overdue principal amount commencing January 1, 2004 and on the first day of each month thereafter until paid in full. In addition, in such circumstances, MDI is obligated to pay all reasonable expenses incurred by Ernst & Young, including attorneys' fees, in enforcing its rights under the note. As of September 30, 2005, MDI had not received a written declaration of default from Ernst & Young. As of September 30, 2005, MDI had not paid and had recorded principal and accrued interest outstanding of $30,800 and $7,158, respectively, with respect to the Ernst & Young note. Ventana Medical Systems, Inc. The note in favor of Ventana Medical Systems matured on December 31, 2003. According to such note, any of the following constitutes an event of default: (i) failure by MDI to pay the principal of the note when due and payable on the maturity date; (ii) failure of MDI to perform any of the covenants, conditions, provisions or agreements contained in the note and such failure remains uncured 15 days after written notice of default has been given; or (iii) the entry of an order for relief under federal bankruptcy laws as to MDI or entry of any order appointing a receiver or trustee or approving a petition in reorganization or other similar relief and if such order, if involuntary, is not satisfied or withdrawn within 60 days after entry thereof, or the filing of a petition by MDI seeking any of the foregoing or consenting thereto, or the filing of a petition to take advantage of any debtor's act, or the making of a general assignment for the benefit of creditors, or admitting in writing its inability to pay debts as they mature. Upon any event of default, Ventana has the option to declare all amounts due under the note immediately due and payable and may take action to accelerate the note, provided that if such event of default relates to bankruptcy or insolvency, all amounts due shall become immediately due and payable without any action on the part of the noteholder. MDI is also obligated to pay on demand all costs and expenses of collection, including reasonable attorneys' fees, incurred or paid by Ventana in enforcing its note on default. Under the note, MDI covenanted to maintain a system of accounting established and administered in accordance with sound business practices to permit the calculation of all amounts due under the note, and to promptly give written notice to Ventana in reasonable detail of the occurrence of any event of default, or any event, condition or act, which with the giving of notice or the passage of time or both, would constitute an event of default. As of September 30, 2005, MDI had not received a written declaration of default from Ventana. As of September 30, 2005, MDI had not paid and had recorded principal and accrued interest outstanding of $21,000 and $2,013, respectively, with respect to the Ventana note. As discussed above, certain of these notes payable do not require the noteholders to provide notice upon an event of default while others require the holder to notify MDI in writing of a declaration of default. There is no guarantee that MDI would be able to cure any existing event of default, or any declared event of default if, or when, the holder provides the required written notice. Indeed, given MDI's current financial condition, receipt of notice from or the pursuit of any remedy by any significant noteholder demanding payment would likely have an adverse material impact on the Company's financial conditon, results of operations and liquidity. In addition, certain noteholders, including the Bridge II noteholders and Ungaretti & Harris LLP, have a security interest in certain assets of the Company. This could have severe implications for the Company and may impair control over its intellectual property and other assets, assuming the Company was unable to cure a default or negotiate a settlement with such lenders, in the event such lenders attempt to realize upon the collateral securing their debt. If the Company continues to be unable to obtain adequate additional financing, any additional financial strain from the declaration of defaults or otherwise may cause the Company to cease operations and seek bankruptcy protection. Item 4. Submission of Matters to Vote of Security None. Item 5. Other Information Please see disclosure under Item 2 of this Part II regarding issuances of common stock during the quarter covered by this report. 28 Please also see disclosure under Note 10 - Legal Proceedings in the Notes to Consolidated Financial Statements herein regarding settlement agreements entered into by the Company. Item 6. Exhibits See Exhibit Index. SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Diagnostics, Inc. /s/ David Weissberg, M.D. ------------------------- David Weissberg, M.D. Chief Executive Officer and Chairman /s/ Robert McCullough --------------------- Robert McCullough Chief Financial Officer Date: November 21, 2005 29 EXHIBIT INDEX Exhibit Number Description ------ ----------- 4.1 Form of subscription agreement to purchase common stock of the company at $0.025 per share. 10.1 Settlement Agreement and Mutual Release effective June 7, 2005, by and between the Cleveland Clinic Foundation and the Company 10.2 General Release and Confidentiality Agreement, entered into October 2005, by and between Eric Gombrich and the Company 10.3 Settlement Agreement and Mutual Release, entered into October 2005, by and among the Lash Group Inc., Peter Gombrich and the Company, with accompanying draft Confession of Judgment. 31.1 Section 302 certification by principal executive officer. 31.2 Section 302 certification by principal financial officer. 32.1 Section 906 certification by principal executive officer. 32.2 Section 906 certification by principal financial officer. 30